300 million people suffer from depression globally. 1 in 3 patients recovering from their first depression episode are likely to relapse into depression, with prolonged fight or flight nervous activity being a leading cause of relapse. Philia Labs is enabling better relapse management by quantifying the body’s fight or flight activity in real time. This will enable clinicians and patients to manage recovery and ultimately prevent depression from becoming a chronic disease. The Australian-based team consists of entrepreneurs, scientists, clinicians and engineers and has several clinical and technical partners in Australia and across the world.